Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Tao, Yungan; Sun, Xu-Shan; Pointreau, Y.; Le Tourneau, Christophe; Sire, Christian; Kaminsky, Marie‐Christine; Coutté, Alexandre; Alfonsi, M.; Calderon, Benôit; Boisselier, Pierre; Martin, Laurent; Miroir, J.; Ramée, Jean‐François; Delord, Jean‐Pierre; Clatot, Florian; Rolland, Frédéric; Villa, Julie; Magné, Nicolas; Eliçin, Olgun; Gherga, Elisabeta; Nguyen, F.; Lafond, Cédrik; Béra, G.; Calugaru, Valentin; Geoffrois, Lionnel; Chauffert, Bruno; Damstrup, Lars; Crompton, Philippa; Ennaji, Abdallah; Gollmer, Kathrin; Nauwelaerts, Heidi; Bourhis, Jean

doi:10.1016/j.ejca.2022.12.015

Public

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Published in European Journal of Cancer • Jan 9, 2023

Authors:

Yungan Tao

Xu-Shan Sun

Y. Pointreau

Abstract

INTRODUCTION: We report long-term efficacy and overall survival (OS) results from a randomised, double-blind, phase 2 study (NCT02022098) investigating xevinapant plus standard-of-care chemoradiotherapy (CRT) vs. placebo plus CRT in 96 patients with unresected locally advanced squamous cell carcinom...

Subject

Medicine

Placebo

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!